A companion diagnostic is a medical device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. The test helps a clinician determine whether a particular therapeutic product’s benefits to patients will outweigh any potential serious side effects or risks1.

  1. Identify patients who are most likely to benefit from a particular therapeutic product.
  2. Identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product.
  3. Monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness.

Recently, NGS-based genomic data have been exploited to better understand disease development and patient characteristics that influence response to a given therapeutic intervention. Cancer, as a disease characterized by and driven by the tumor genetic landscape, is particularly amenable to NGS-based diagnostic approaches. NGS-based technologies are particularly well suited to studying cancer disease development, progression and emergence of resistance, all key factors in the development of next-generation cancer diagnostics2.

Designed for 100% amplicon coverage of coding region of BRCA1 and BRCA2 genes, the VariantPro™ BRCA1 and BRCA2 Panel offers cost-effective, minimal hands-on, ultra-high resolution sequence analysis for revealing clinically relevant mutations in BRCA1 and BRCA2 genes.

VariantPro Targeted Sequencing
The VariantPro system is an innovative multiplex PCR based targeted sequencing method that accomplishes target selection, library preparation and molecular tagging in a simple one-step workflow…

Exome Sequencing
Exome sequencing is an efficient strategy to selectively sequence the coding regions of the genome as a less expensive but still effective alternative to whole genome sequencing. The human exome contains about 180,000 exons. These constitute about 1% of the human genome…

With the emergence of RNA sequencing (RNA-seq) technologies, RNA-based biomolecules hold expanded promise for their diagnostic, prognostic and therapeutic applicability in various diseases, including cancers and infectious diseases. Detection of gene fusions and differential expression of known disease-causing transcripts by RNA-seq represent some of the most immediate opportunities. However, it is the diversity of RNA species (including miRNAs) detected through RNA-seq that holds new promise for the multi-faceted clinical applicability of RNA-based measures, including the potential of extracellular RNAs as non-invasive diagnostic indicators of disease3.

miRNAs are known to play important roles in the diagnosis and prognosis of many cancers, and they are useful in developing targeted therapies.

microRNA Profiling Services
microRNAs (miRNAs) are small noncoding RNA molecules that function broadly as negative regulators of gene expression to control a wide range of cellular processes. miRNA sequencing is a new method and a powerful tool to identify and quantitatively decode the entire population of miRNAs in your sample.…

RNA Sequencing Services
Our comprehensive sequencing services make use of the latest in next-gen sequencing technologies. Illumina’s industry-leading RNA sequencing methods enable discovery and profiling of RNAs without prior genome annotation, and allow for the most accurate detection and quantification of rare RNA…

Antibodies have several properties that make them excellent indicators of disease, and their detection forms the basis of many in vitro diagnostic tests.

The immune system also produces autoantibodies in response to a large number of pathogenic processes. The appearance of autoantibodies can precede disease symptoms by many years and, due to the inherent amplification of the immune system, they are readily detectable, making them ideal for presymptomatic and early diagnosis of disease4.

Autoantibody biomarkers are very helpful tools for diagnosis, assessment and monitoring of disease activity, differential diagnosis of clinical manifestations, prediction of the disease course and stratified therapy, and are key to personalized medicine5.

Phosphopeptide Binding Microarray Service
The PepArray™ technology also provides the flexibility of synthesizing microarrays containing probes with modifications such as phosphopeptides, peptidomimetics, other amino acid analogs or various other types of modifications. Incorporation of modifications greatly increases the number of applications for these microarrays…

Cancer Antigen Arrays
These arrays offer the possibility for quick and specific screening the binding and selectivity of therapeutic antibodies. The standard cancer antigen array includes a comprehensive list of NCI priority-ranked cancer vaccine target antigens based on predefined and preweighted objective criteria, proteins targeted by anticancer therapies (marked as thera in the content list), and RTK receptors as important cancer antigens, such as EGFR etc...

microRNA

Drug Efficacy

The ability to predict drug efficacy based on the genetic makeup of individual tumors, and to make treatment decisions based on those differences is the hallmark of precision medicine.

Drug Resistance

Drug resistance (chemoresistance) is one of the major obstacles for improving the prognosis of cancer patients.

Drug Toxicity

Identifying patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product is a critical part of the development of personalized therapies

LC Sciences offers a range of services applicable to clinical cancer research . Contact us to find out more.


VariantPro Targeted Sequencing

The VariantPro system is an innovative multiplex PCR based targeted sequencing method that accomplishes target selection, library preparation and molecular tagging in a simple one-step workflow. [learn more…]

Exome Sequencing

Exome sequencing is an efficient strategy to selectively sequence the coding regions of the genome as a less expensive but still effective alternative to whole genome sequencing. [learn more…]


Cancer Antigen Arrays

The additional knowledge gained by studying the response to antigens at the epitope level will help us further understand anti-tumor immunity and may also help us to monitor cancer progress and cancer vaccine efficacy in the future. [learn more…]

Protein Profiling Arrays

Systems Biology has emerged as an effective approach to studying complex interactions within biological systems. By studying entire networks or pathways, we can better understand the underlying structure of cell signaling networks. [learn more…]


microRNA Profiling

microRNAs are small noncoding RNA molecules that function broadly as negative regulators of gene expression to control a wide range of cellular processes. [learn more…]

RNA Sequencing

Our comprehensive sequencing services make use of the latest in next-gen sequencing technologies. Illumina’s industry-leading RNA sequencing methods enable discovery [learn more…]